Novo has historically stayed away from large-scale mergers and acquisitions ... could prove complementary to Wegovy in obesity. Novo Nordisk accounts for 34% of the global diabetes market ...

Novo Nordisk ... capacity at scale and speed, while providing future optionality and flexibility for Novo Nordisk’s existing supply network.” It is connected to a larger transaction in which ...

The PMCPA concurred, saying that it was “very concerned that Novo Nordisk did not recognise that this was a large-scale Saxenda promotional campaign, which Novo Nordisk knowingly paid for and ...

Novo Nordisk is seeking up to $830 million in damages from KBP Biosciences, according to a ruling by a Singapore court, as ...

Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...

Novo Nordisk (NYSE: NVO) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly) that's also probably bad news for Hims & Hers Health (NYSE: HIMS).

All semaglutide doses are now being “continuously shipped” to wholesalers and “meeting or exceeding expected U.S. demand,” Novo Nordisk said in a Friday press release. The company added ...

Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other perks.

Novo Nordisk's profit of DKK28.23 billion also topped estimates. Wegovy sales soared 107% at constant exchange rates to DKK19.87 billion, just below estimates. Ozempic sales rose 12% to DKK33.85 ...

Revenues in the biopharma industry continued to boom in the fourth quarter of last year, following a pattern seen ...